PACTR201507001055177尚未招募未知
EVALUATION OF THE EFFICACY OF HEPANTIVIR (SECURININE) IN PATIENTS WITH CHRONIC HEPATITIS B INFECTIO
BOLAR PHARMACEUTICALS LTD0 个研究点目标入组 50 人开始时间: 2015年3月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 60 Year(s)（—）
- 性别
- All
入选标准
- •Fifty consecutive and consenting patients being managed by gastroenterology unitwith clinical and biochemical features as well as serological evidence of chronic hepatitis B infection and who meet the study criteria- 18 years and above, HBsAg positive with elevated serum ALT, Serum HBV DNA > 2000iu/ml
排除标准
- •No consent, presence of underlying liver malignancy, presence of co-morbidities eg end-organ failure
研究者
相似试验
招募中
不适用
Clinical Performance Evaluation of Sansure Hepatitis C Virus RNA Quantitative Fluorescence Diagnostic Kit (PCR-Fluorescence Probing)Hepatitis C is an inflammation of the liver caused by the hepatitis C virus (HCV). HCV is transmitted through blood, for example through drug use. Hepatitis C is often chronic, but can almost always be cured in a maximum of three months. Without treatment, hepatitis C can lead to liver failure or liver cancer.DRKS00034144Sansure Biotech Inc.144
招募中
不适用
Clinical Performance Evaluation of Sansure Hepatitis B Virus DNA Quantitative Fluorescence Diagnostic Kit (PCR-Fluorescence Probing)Hepatitis B is an inflammation of the liver caused by the HBV virus. It is easily transmitted, especially during sex and through contaminated syringes and accessories. The infection can become chronic, i.e. make you permanently illDRKS00034136Sansure Biotech Inc.144
尚未招募
2 期
Doxorubicin Transdrug® in Advanced Hepatocellular Carcinoma.HepatoCellular CarcinomaCancer - LiverACTRN12608000082303ORION Clinical Services (Australia) Pty Ltd200
尚未招募
2 期
The Evaluation of effectiveness of heparin nebulizer in reduction of respiratory distress in patients with COVID-19COVID-19.COVID-19, virus identifiedU07.1IRCT20210513051275N1Islamic Azad University60
招募中
3 期
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84